Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

September 2016 in “ JCI insight ”

Julian Mackay-Wiggan, Ali Jabbari, Nhan Nguyen, Jane E. Cerise, Charlotte Clark, Grace Ulerio, Megan Furniss, Roger Vaughan, Angela M. Christiano, Raphael Clynes

ruxolitinib JAK1/2 inhibitor alopecia areata hair regrowth inflammatory markers gene expression analysis AA

TLDR Ruxolitinib effectively regrows hair in most patients with severe hair loss.

In a pilot study from 2016, researchers tested the effectiveness of oral ruxolitinib, a JAK1/2 inhibitor, on 12 patients with moderate-to-severe alopecia areata (AA). The patients took 20 mg of ruxolitinib twice daily for 3-6 months, with a follow-up period of 3 months after discontinuation. The study reported that 75% (9 out of 12) of the patients experienced significant hair regrowth, with an average of 92% hair regrowth by the end of the treatment period. No serious adverse effects were reported, and gene expression analysis showed a decrease in inflammatory markers and an increase in hair-specific markers. The study concluded that ruxolitinib was effective in treating AA, but emphasized the need for larger, randomized controlled trials to confirm its safety and efficacy.

View this study on insight.jci.org →

Discuss this study in the Community →

Research cited in this study

10 / 10 results

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

222 citations, September 2016 in “JCI insight”

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

research Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata

157 citations, December 2015 in “Journal of the American Academy of Dermatology”

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

184 citations, February 2015 in “EBioMedicine”

A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations, August 2014 in “Nature medicine”

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis

185 citations, June 2014 in “Journal of Investigative Dermatology”

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

research Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity

717 citations, June 2010 in “Nature”

Alopecia areata involves both innate and adaptive immunity, with specific genes linked to the disease.

research Alopecia Areata Update

244 citations, January 2010 in “Journal of the American Academy of Dermatology”

The document says current treatments for alopecia areata do not cure or prevent it, and it's hard to judge their effectiveness due to spontaneous remission and lack of studies.

research Alefacept for Severe Alopecia Areata: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial

43 citations, November 2009 in “Archives of dermatology”

Alefacept does not effectively treat severe alopecia areata.

research Interventions for Alopecia Areata

164 citations, April 2008 in “Cochrane library”

Current treatments for alopecia show no significant long-term benefits.

research Familial Aggregation of Alopecia Areata

295 citations, January 2006 in “Journal of the American Academy of Dermatology”

Alopecia areata, a common autoimmune hair loss condition, often runs in families.

Related Research

10 / 10 results

research Efficacy of Janus Kinase Inhibitors in Adult Patients With Alopecia Areata

August 2023 in “International journal of research in dermatology”

Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.

research The Usefulness and Wellbeing of Tofacitinib in the Treatment of Alopecia Areata

October 2022 in “Journal of Armed Forces Medical College, Bangladesh”

Tofacitinib is effective and safe for treating alopecia areata.

research Clinical Response to Adjunctive Platelet-Rich Plasma Injections in a Patient with Alopecia Universalis on Oral Tofacitinib

1 citations, December 2021 in “JAAD case reports”

A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.

research Efficacy of Systemic Minoxidil and Tofacitinib Combination in Treatment-Resistant Alopecia Universalis

1 citations, October 2020 in “Journal of Cosmetic Dermatology”

Using minoxidil and tofacitinib together can effectively treat severe hair loss.

research Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients

48 citations, November 2017 in “Journal of the American Academy of Dermatology”

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

Research cited in this study

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

research Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata

research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis

research Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity

research Alopecia Areata Update

research Alefacept for Severe Alopecia Areata: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial

research Interventions for Alopecia Areata

research Familial Aggregation of Alopecia Areata

Related Community Posts Join

community Ruxolitinib - Start of a case study

community No hair, don't care! [24/F] :)

community What else is good. Besides the big 3.

Related Research

research Efficacy of Janus Kinase Inhibitors in Adult Patients With Alopecia Areata

research The Usefulness and Wellbeing of Tofacitinib in the Treatment of Alopecia Areata

research Clinical Response to Adjunctive Platelet-Rich Plasma Injections in a Patient with Alopecia Universalis on Oral Tofacitinib

research Efficacy of Systemic Minoxidil and Tofacitinib Combination in Treatment-Resistant Alopecia Universalis

research Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients

research Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient

research A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata

research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

research Transient Efficacy of Tofacitinib in Alopecia Areata Universalis